Recommended Adult Immunization Schedule, United States, 2024*

Clinical Guidelines12 January 2024Recommended Adult Immunization Schedule, United States, 2024FREENeil Murthy, MD, MPH, MSJ, A. Patricia Wodi, MD, Veronica V. McNally, JD, Matthew F. Daley, MD, and Sybil Cineas, MD, on behalf of the Advisory Committee on Immunization Practices†Neil Murthy, MD, MPH, MSJCenters for Disease Control and Prevention, Atlanta, Georgia (N.M., A.P.W.)Search for more papers by this author, A. Patricia Wodi, MDCenters for Disease Control and Prevention, Atlanta, Georgia (N.M., A.P.W.)Search for more papers by this author, Veronica V. McNally, JDFranny Strong Foundation, West Bloomfield, Michigan (V.V.M.)Search for more papers by this author, Matthew F. Daley, MDInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado (M.F.D.)Search for more papers by this author, and Sybil Cineas, MDThe Warren Alpert Medical School of Brown University, Providence, Rhode Island (S.C.).Search for more papers by this author, on behalf of the Advisory Committee on Immunization Practices†Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-3269 Eligible for CME Point-of-Care SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In October 2023, the Advisory Committee on Immunization Practices (ACIP) voted to approve the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024. The 2024 adult immunization schedule, available at www.cdc.gov/vaccines/schedules/hcp/imz/adult.html, summarizes ACIP recommendations in the cover page, tables, notes, appendix, and addendum (Figure). The full ACIP recommendations for each vaccine are available at www.cdc.gov/vaccines/hcp/acip-recs/index.html. The 2024 schedule has also been approved by the director of the Centers for Disease Control and Prevention (CDC) and by the American College of Physicians (www.acponline.org), the American Academy of Family Physicians (www.aafp.org), the American College of Obstetricians and Gynecologists (www.acog.org), the American College of Nurse-Midwives (www.midwife.org), the American Academy of Physician Associates (www.aapa.org), the American Pharmacists Association (www.pharmacist.com), and the Society for Healthcare Epidemiology of America (www.shea-online.org).Figure. Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024. Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint Figure. Continued Download figure Download PowerPoint The ACIP develops recommendations on the use of each vaccine after in-depth review of vaccine-related data, such as the epidemiology and burden of vaccine-preventable disease (VPD), vaccine efficacy and effectiveness, vaccine safety, quality of evidence, feasibility of program implementation, health equity impact, and economic analyses of immunization policy (1, 2). ACIP recommendations can be complex and challenging to implement. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist health care providers in implementing current ACIP recommendations. The use of vaccine trade names in this article and in the schedule is for identification purposes only and does not imply endorsement by the ACIP or CDC.Changes to the 2024 Adult Immunization ScheduleCOVID-19 vaccination (3). The COVID-19 vaccination section was updated to reflect the new COVID-19 vaccination recommendations that were approved during an ACIP public meeting held on 12 September 2023. All adults are now recommended to receive at least 1 dose of the updated (2023–2024 Formula) COVID-19 vaccine. The “Routine vaccination” section describes the vaccine recommendations for the general population, while the “Special situations” section describes the vaccine recommendations for persons who are moderately or severely immunocompromised. The number of doses needed and intervals between doses may vary based on a patient’s immunization history, their immunocompromised status, and the vaccine product used.Haemophilus influenzae type b (Hib) vaccination. Recommendations for Hib vaccination have not changed.Hepatitis A (HepA) vaccination (4). Minor changes were made to the “Routine vaccination” and “Special situations” sections to improve clarity in the language.Hepatitis B (HepB) vaccination (5). Additional context was provided in the “Routine vaccination” section to describe the risk-based recommendation for persons 60 years of age and older. The text now reads, “Age 60 years or older without known risk factors for hepatitis B virus infection may receive a HepB vaccine series. Age 60 years or older with known risk factors for hepatitis B virus infection should receive a HepB vaccine series. Any adult age 60 years of age or older who requests HepB vaccination should receive a HepB vaccine series.” A note was added at the end of the “Routine vaccination” section describing the shared clinical decision-making recommendation for persons 60 years of age and older with diabetes.Human papillomavirus (HPV) vaccination (6). Guidance on interrupted schedules was removed because that information is presented on the cover page. To add clarity, the words “of any valency” were added to the bullet “No additional dose recommended when any HPV vaccine series of any valency has been completed using the recommended dosing intervals.” Lastly, a resource was added to assist health care providers with shared clinical decision-making recommendations for HPV vaccination.Influenza vaccination (7). For the 2023–2024 influenza season, routine annual influenza vaccination continues to be recommended for all persons aged 6 months and older who do not have contraindications.The composition of 2023–2024 U.S. influenza vaccines includes an update to the influenza A(H1N1)pdm09 component. All seasonal influenza vaccines available for the 2023–2024 season are quadrivalent. The egg-based vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/4897/2022 (H1N1)pdm09–like virus, an influenza A/Darwin/9/2021 (H3N2)–like virus, an influenza B/Austria/1359417/2021 (Victoria lineage)–like virus, and an influenza B/Phuket/3073/2013 (Yamagata lineage)–like virus. The cell culture–based and recombinant vaccines will contain HA derived from an influenza A/Wisconsin/67/2022 (H1N1)pdm09–like virus, an influenza A/Darwin/6/2021 (H3N2)–like virus, an influenza B/Austria/1359417/2021 (Victoria lineage)–like virus, and an influenza B/Phuket/3073/2013 (Yamagata lineage)–like virus.Bullets referring to having an egg-based allergy were removed from the “Special situations” section, because any influenza vaccine (either egg-based or non–egg-based) indicated for the recipient’s age and health status can be used. A note explaining that any vaccine product appropriate for age and health status can be used for persons with an egg allergy was added at the end of the “Special situations” section.Measles, mumps, and rubella (MMR) vaccination (8). Minor changes were made to the “Routine vaccination” section to improve clarity in the language.Meningococcal vaccination (9). Menactra (MenACWY-D) was removed from the Notes section because this product is no longer distributed in the United States. A hyperlink to a resource that describes shared clinical decision making for MenB vaccination is provided. Finally, information on the use of the new pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp, Penbraya) was provided at the end of the Meningococcal Notes section.Mpox vaccination (10). Mpox is a new addition to the Notes section of the adult immunization schedule. Risk factors that warrant routine Jynneos (Bavarian Nordic) vaccination are listed. Bullets about the use of Jynneos among health care providers and in pregnant persons are provided at the end of the Mpox Notes section.Pneumococcal vaccination (11). Minor edits were made throughout the “Routine vaccination” and “Special situations” sections to provide clarity on the guidance and minimum intervals between doses of pneumococcal vaccines.Polio vaccination (12). The “Routine vaccination” section was revised and now states that adults who are known or suspected to be unvaccinated or incompletely vaccinated should complete the 3-dose inactivated poliovirus vaccine (IPV) primary series. Additionally, a statement was added stating that most adults born and raised in the United States can assume that they were vaccinated against polio as children. The “Special situations” section describes that adults who are at increased risk for exposure to poliovirus and who have completed the primary series may receive a one-time, lifetime IPV booster dose.Respiratory syncytial virus (RSV) vaccination (13, 14). RSV is a new addition to the Notes section of the adult immunization schedule. The “Routine vaccination” section describes the use of Abrysvo (Pfizer) during 32 to 36 weeks’ gestation. A sub-bullet was added stating that either maternal RSV vaccination or infant immunization with nirsevimab (RSV monoclonal antibody) is recommended to prevent RSV lower respiratory tract infection in infants. A note was added stating that certain jurisdictions may have RSV seasonality that differs from most of the continental United States and that health care providers should follow guidance from public health authorities on timing of administration based on local RSV seasonality. The “Special situations” section describes the shared clinical decision-making recommendation for vaccination among persons 60 years of age and older; either Abrysvo (Pfizer) or Arexvy (GSK) may be used. A hyperlink to a resource that describes shared clinical decision-making recommendations for RSV vaccination is provided. Finally, a note was added describing the risk factors and medical conditions that health care providers should consider when thinking about a patient’s risk for severe RSV disease and if such patients would benefit from vaccination.Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination (15). A note was added at the end of the Tdap section to clarify that a dose of Tdap received at 10 years of age may be counted as the adolescent dose routinely recommended at age 11 to 12 years.Varicella vaccination. Routine recommendations for varicella vaccination have not changed.Zoster vaccination. Routine recommendations for zoster vaccination have not changed.Revised Content, Format, and GraphicsCover Page. The cover page of the 2024 schedule provides basic instructions on how to use the schedule to systematically identify vaccination needs of adults and lists routinely recommended vaccines and their standardized abbreviations and trade names. Major edits to the cover page include the following: adding a fifth step in the “How to use the adult immunization schedule” box, which directs health care providers to refer to the new addendum section to review new or updated ACIP recommendations that occur after the schedule is published; adding RSV vaccines, Mpox vaccine (Jynneos), and pentavalent meningococcal vaccine (Penbraya) to the list of vaccines; and removing Menactra and bivalent mRNA COVID-19 vaccines from the list of vaccines. Additionally, information that was previously presented on the cover page, such as injury claims and travel vaccine recommendations, has now been moved to an “Additional Information” section on the first page of the Notes, to harmonize the way in which this information is presented in the 2024 child and adolescent immunization schedule. As in past annual immunization schedules, hyperlinks are provided where health care providers can download the CDC Vaccine Schedules app and access reference materials for the surveillance of VPDs, including case identification and disease outbreak response. Instructions on reporting suspected cases of reportable VPDs to local or state health departments and significant postvaccination adverse events to the Vaccine Adverse Event Reporting System (VAERS) are listed. Hyperlinks to other resources, such as vaccine information statements and shared clinical decision-making guidance, are also provided.Table 1. Recommended Adult Immunization Schedule by Age Group. Table 1 describes routine vaccination recommendations for adults by age. For 2024, the overlaying text for the COVID-19 row has changed. The text overlay now states “1 or more doses of updated (2023–2024 Formula) vaccine.” Additionally, RSV and Mpox vaccines have been added as rows to this table. The RSV row is purple for adults 19 to 49 years of age, with overlaying text “seasonal administration during pregnancy,” reflecting the recommendation for the use of Abrysvo RSV vaccine (Pfizer) during pregnancy. The RSV row is light blue starting at age 60 years and older, indicating that the recommendation for RSV vaccination among adults 60 years of age and older is based on shared clinical decision making. The Mpox row is purple across all ages, reflecting the risk-based recommendation for Jynneos vaccination.Table 2. Recommended Adult Immunization Schedule by Medical Condition and Other Indications. Table 2 describes vaccination recommendations for adults based on medical conditions or other indications. This table has been substantially revised in the 2024 schedule. First, a header sentence has been added that describes that medical conditions are often not mutually exclusive and that health care providers should refer to all relevant columns when multiple conditions are present. Second, the yellow, purple, and gray colors of the legend have been redefined. The new definitions of these colors were intended to be more focused and narrow such that the recommendations for vaccination based on that medical indication are more evident. Brown was introduced as a new legend color, which indicates that additional vaccine doses are needed based on medical condition or other indication. Because of the new color definitions, most of the vaccine rows in Table 2 have been recolored. In addition to the changes in the legend colors, RSV and Mpox vaccines have been added as rows to this table. The RSV row is yellow with overlaying text “seasonal administration” for pregnancy indicating that the use of Abrysvo RSV vaccine (Pfizer) in pregnancy is based on RSV seasonality. For the rest of the medical indications listed, the color of this row is light blue, reflecting that the recommendation for vaccination among adults 60 years of age and older is based on shared clinical decision making. The Mpox row is purple across all of the medical indications listed, indicating the risk-based recommendation for Jynneos vaccination. Finally, under the diabetes column of the HepB row, a blue bar was added to indicate that the recommendation for vaccination for persons 60 years of age and older with diabetes is based on shared clinical decision making.Notes. Recommended Adult Immunization Schedule. The first page of the Notes section begins with a new “Additional Information” section. This information has been harmonized to the greatest extent possible with the “Additional Information” section on the first page of the Notes section of the 2024 child and adolescent immunization schedule. Many topics that were originally included in the cover page have been moved to this new “Additional Information” section. The text for vaccine injury compensation was revised to add Mpox and RSV to the list of vaccines not covered by the National Vaccine Injury Compensation Program. Mpox is covered by the Countermeasures Injury Compensation Program. Similar to the schedules in previous years, each recommended vaccine for adults in Tables 1 and 2 is accompanied by a note designed to provide additional information on routine vaccination and recommendations in special situations. The RSV and Mpox notes are new additions to the 2024 adult immunization schedule. In addition, new and updated recommendations for influenza vaccine, IPV, meningococcal vaccine, and COVID-19 vaccine are provided in the notes. Changes were also made to the HepA, HepB, HPV, MMR, pneumococcal vaccines, and Tdap to either provide additional context or improve clarity in the language. All vaccines identified in Tables 1 and 2 (except zoster vaccine) also appear in the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024 (www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html). The notes for vaccines that appear in both the adult immunization schedule and the child and adolescent immunization schedule have been harmonized to the greatest extent possible.Appendix. Recommended Adult Immunization Schedule. The appendix lists all of the contraindications and precautions to each of the vaccines listed in the 2024 adult immunization schedule. Two new rows for COVID-19 vaccines were added to the appendix. The first row lists the contraindications and precautions to mRNA vaccines (Pfizer–BioNTech and Moderna), while the second row lists the contraindications and precautions to the protein subunit vaccine (Novavax). In the Hib row, information about latex allergy was removed from the “contraindicated or not recommended” column because vials of Hib products no longer contain latex. In the MenACWY row, references to Menactra were removed because this product is no longer available in the United States and all doses expired in October 2023. Rows were added for RSV, Mpox, and pentavalent meningococcal (Penbraya) vaccines to describe contraindications and precautions to those vaccines.Addendum. Recommended Adult Immunization Schedule. The addendum is a new addition to the adult immunization schedule. This section summarizes any changes or updates to ACIP recommendations that occur after the schedule was voted on and approved by ACIP in October 2023. The addendum provides summarized bullets describing any new or updated ACIP recommendations. Health care providers are encouraged to refer to corresponding MMWR articles (when available) for detailed guidance on new or updated recommendations.References1. Centers for Disease Control and Prevention. Charter of the Advisory Committee on Immunization Practices. 28 March 2022. Accessed at www.cdc.gov/vaccines/acip/committee/acip-charter.pdf on 8 December 2023. Google Scholar2. Centers for Disease Control and Prevention. ACIP Evidence to Recommendations Framework. Accessed at www.cdc.gov/vaccines/acip/recs/grade/downloads/acip-evidence-recs-framework.pdf on 8 December 2023. Google Scholar3. Centers for Disease Control and Prevention. Use of COVID-19 Vaccines in the United States. Accessed at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html on 8 December 2023. Google Scholar4. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69:1-38. [PMID: 32614811] doi:10.15585/mmwr.rr6905a1 CrossrefMedlineGoogle Scholar5. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477-483. [PMID: 35358162] doi:10.15585/mmwr.mm7113a1 CrossrefMedlineGoogle Scholar6. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702. [PMID: 31415491] doi:10.15585/mmwr.mm6832a3 CrossrefMedlineGoogle Scholar7. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season. MMWR Recomm Rep. 2023;72:1-25. doi:10.15585/mmwr.rr7202a1 CrossrefGoogle Scholar8. McLean HQ, Fiebelkorn AP, Temte JL, et al; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1-34. [PMID: 23760231] MedlineGoogle Scholar9. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1-41. [PMID: 33417592] doi:10.15585/mmwr.rr6909a1 CrossrefMedlineGoogle Scholar10. Centers for Disease Control and Prevention. Clinical Guidance and Next Steps. Accessed at www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf on 8 December 2023. Google Scholar11. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023;72:1-39. [PMID: 37669242] doi:10.15585/mmwr.rr7203a1 CrossrefMedlineGoogle Scholar12. Kidd S, Clark T, Routh J, et al. Use of inactivated polio vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1327-1330. [PMID: 38060431] doi:10.15585/mmwr.mm7249a3 CrossrefMedlineGoogle Scholar13. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115-1122. [PMID: 37824423] doi:10.15585/mmwr.mm7241e1 CrossrefMedlineGoogle Scholar14. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:793-801. [PMID: 37471262] doi:10.15585/mmwr.mm7229a4 CrossrefMedlineGoogle Scholar15. Havers FP, Moro PL, Hunter P, et al. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:77-83. [PMID: 31971933] doi:10.15585/mmwr.mm6903a5 CrossrefMedlineGoogle ScholarAppendix A: Members of the ACIP and the ACIP Combined Immunization Work GroupUnless otherwise indicated, the members listed were nonauthor contributors to this article.Members of the ACIPGrace M. Lee, MD, MPH (Chair), Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CaliforniaMelinda Wharton, MD, MPH (Executive Secretary), National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaLynn Bahta, RN, MPH, CPH, Infectious Disease, Epidemiology, Prevention & Control Division, Minnesota Department of Health, Saint Paul, MinnesotaBeth P. Bell, MD, MPH, Department of Global Health, School of Public Health, University of Washington, Seattle, WashingtonOliver Brooks, MD, Watts HealthCare Corporation, Los Angeles, CaliforniaWilbur H. Chen, MD, MS, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MarylandSybil Cineas, MD, The Warren Alpert Medical School of Brown University, Brown Combined Residency in Internal Medicine and Pediatrics, Providence, Rhode IslandMatthew F. Daley, MD, Institute for Health Research, Kaiser Permanente Colorado, Aurora, ColoradoCamille Nelson Kotton, MD, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsJamie Loehr, MD, Cayuga Family Medicine, Ithaca, New YorkSarah S. Long, MD, Drexel University College of Medicine, Section of Infectious Diseases, St. Christopher's Hospital for Children, Philadelphia, PennsylvaniaVeronica V. McNally, JD, Franny Strong Foundation, West Bloomfield, MichiganKatherine A. Poehling, MD, MPH, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North CarolinaPablo J. Sánchez, MD, The Ohio State University, Nationwide Children's Hospital, Divisions of Neonatal-Perinatal Medicine and Pediatric Infectious Diseases, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OhioNirav D. Shah, MD, JD, Maine Center for Disease Control and Prevention, Augusta, MaineHelen Keipp Talbot, MD, Vanderbilt University, Nashville, TennesseeACIP Combined Immunization Work GroupACIP Members: Sybil Cineas (ACIP Work Group Chair)*; Matthew F. Daley*; Veronica V. McNally*Liaison Representatives: John Epling; Sarah Coles; Rhoda Sperling; Holly Fontenot; Amy Middleman; Sandra Fryhofer; Sarah McQueen; Marie-Michele Leger; Mary-Margaret Fill; William Schafner; Ken Schmader; Patsy Stinchfield; Pia Pannaraj; Preeti Mehrotra; Robert Hopkins; Kelly Goode; Caitlin Newhouse; Molly HowellEx Officio Members: David Kim; Jane Kim; Susan Farrall; Uzo ChukwumaConsultants: Hank Bernstein; Peter Szilagyi; Diane Peterson; Carolyn Bridges; Karen Ketner; Kathleen Harriman; Litjen Tan; Susan LettCDC Co-Leads: A. Patricia Wodi*; Neil Murthy** Authored the article. Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Neil Murthy, MD, MPH, MSJ; A. Patricia Wodi, MD; Veronica V. McNally, JD; Matthew F. Daley, MD; Sybil Cineas, MDAffiliations: Centers for Disease Control and Prevention, Atlanta, Georgia (N.M., A.P.W.)Franny Strong Foundation, West Bloomfield, Michigan (V.V.M.)Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado (M.F.D.)The Warren Alpert Medical School of Brown University, Providence, Rhode Island (S.C.).Disclosures: To maintain the integrity of the Advisory Committee on Immunization Practices (ACIP), the U.S. Department of Health and Human Services has taken steps to ensure there is technical adherence to ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed or avoided altogether through preappointment and postappointment considerations. Individuals with particular vaccine-related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest and, if any are found, are asked to divest or forgo certain vaccine-related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare their conflicts. Members with conflicts are not permitted to vote if the conflict involves the vaccine or biologic being voted on. Details can be found at www.cdc.gov/vaccines/acip/committee/index.html. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-3269.Corresponding Author: Neil Murthy, MD, MPH, MSJ, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027; e-mail, nmurthy@cdc.gov.Author Contributions: Conception and design: N. Murthy, A.P. Wodi.Analysis and interpretation of the data: A.P. Wodi, N. Murthy.Drafting of the article: N. Murthy.Critical revision for important intellectual content: S. Cineas, M.F. Daley, N. Murthy, A.P. Wodi, V.V. McNally.Final approval of the article: S. Cineas, M.F. Daley, V.V. McNally, N. Murthy, A.P. Wodi.Administrative, technical, or logistic support: A.P. Wodi, N. Murthy.Collection and assembly of data: N. Murthy, A.P. Wodi.This article was published at Annals.org on 12 January 2024.* The 2024 adult immunization schedule appeared in Annals of Internal Medicine and on the Centers for Disease Control and Prevention website at www.cdc.gov/vaccines/schedules. An announcement summarizing changes to the 2024 adult immunization schedule was published in the Morbidity and Mortality Weekly Report on 12 January 2024. Readers can cite the 2024 adult immunization schedule as follows: Murthy N, Wodi AP, McNally VV, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2024. Ann Intern Med. Epub 12 Jan 2024. doi:10.7326/M23-3269† The 2024 adult immunization schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and was prepared by the ACIP Combined Immunization Schedule Work Group; Neil Murthy (Centers for Disease Control and Prevention, Atlanta, Georgia); A. Patricia Wodi (Centers for Disease Control and Prevention, Atlanta, Georgia); Veronica V. McNally (Franny Strong Foundation, West Bloomfield, Michigan); Matthew F. Daley (Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado); and Sybil Cineas (The Warren Alpert Medical School of Brown University, Providence, Rhode Island). For a list of members of the ACIP and the ACIP Combined Immunization Schedule Work Group, see Appendix A. Nextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoQuality Health Communication Is Critical to Optimal Adult Immunization Scott C. Ratzan , Ruth M. Parker , Kenneth H. Rabin , and Glen J. Nowak Metrics Cited byQuality Health Communication Is Critical to Optimal Adult ImmunizationScott C. Ratzan, MD, MPA, MA, Ruth M. Parker, MD, Kenneth H. Rabin, MA, PhD, and Glen J. Nowak, MA, PhD Latest Keywords Infectious diseases Preventive medicine Vaccines ePublished: 12 January 2024 PDF downloadLoading ...